Artelo Biosciences, Inc. (ARTL)
$
10.54
+7.35 (69.73%)
Key metrics
Financial statements
Free cash flow per share
-4.1842
Market cap
22.4 Million
Price to sales ratio
0
Debt to equity
-0.5448
Current ratio
0.1719
Income quality
0.8699
Average inventory
0
ROE
19.3742
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Artelo Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies aimed at modulating the endocannabinoid system, recently incurred an income tax expense of $0.00 indicating its tax obligations. In assessing its operational efficiency, the gross profit ratio stands at 0.00 which reflects the effectiveness of the company's production and sales efforts. With operating expenses totaling $11,404,000.00 the company has accounted for the various costs associated with its operations. Artelo also reported an income before tax of -$12,879,000.00 showcasing its pre-tax profitability, while the gross profit reached $0.00 highlighting the company's profitability derived from its core activities. The product candidate pipeline includes promising developments such as ART27.13, a synthetic G protein-coupled receptor agonist in Phase 1b/2a clinical trials for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal aimed at addressing inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for the treatment of prostate and breast cancer, as well as PTSD. Collaborating with Trinity College Dublin, Artelo is investigating ART27.13 specifically for cancer cachexia, demonstrating its commitment to addressing unmet medical needs. Founded in 2011 and originally named Reactive Medical, Inc., the company rebranded to Artelo Biosciences, Inc. in April 2017 and is headquartered in Solana Beach, California. In terms of financial accessibility, the stock is affordable at $5.62 making it suitable for budget-conscious investors. However, it has a low average trading volume of 1,247,503.00 indicating lower market activity. With a market capitalization of $22,395,097.00 Artelo is classified as a small-cap player within the biopharmaceutical sector. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall landscape of healthcare innovation. Positioned in the Healthcare sector, Artelo Biosciences, Inc. drives innovation and growth, reflecting its strategic focus on developing therapeutic solutions that leverage the endocannabinoid system for various medical applications.
Is Artelo Biosciences, Inc. (ARTL) a good investment?
Investing in Artelo Biosciences, Inc. (ARTL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Artelo Biosciences, Inc. (ARTL)'s stock forecast?
Analysts predict Artelo Biosciences, Inc. stock to fluctuate between $3.15 (low) and $85.80 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Artelo Biosciences, Inc.'s market capitalization?
As of 2026-03-27, Artelo Biosciences, Inc.'s market cap is $22,395,097, based on 2,124,772 outstanding shares.
How does Artelo Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Artelo Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Artelo Biosciences, Inc. (ARTL) stock?
To buy Artelo Biosciences, Inc. (ARTL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ARTL. Place an order (Market, Limit, etc.).
What is the best time to invest in Artelo Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Artelo Biosciences, Inc. stock ever split?
Artelo Biosciences, Inc.'s last stock split was 1:3 on 2026-03-10.
How did Artelo Biosciences, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$5.47 | Growth: 438.09%.
Where can I find Artelo Biosciences, Inc.'s investor relations reports?
Visit https://www.artelobio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Artelo Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Artelo Biosciences, Inc. stock?
All-time high: $28.60 (2025-07-10) | All-time low: $0.82 (2025-04-09).
What are the key trends affecting Artelo Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 37,410 shares, a decline of 29.6% from the February 26th total of 53,146 shares. Currently, 6.0% of the company's shares are sold short. Based on an
benzinga.com
Artelo Biosciences requested the withdrawal of its Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.
globenewswire.com
Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication
benzinga.com
ART27.13 is a peripherally selective synthetic cannabinoid.
globenewswire.com
Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac
globenewswire.com
BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients.
globenewswire.com
Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology
defenseworld.net
Artelo Biosciences (NASDAQ: ARTL) held its 2025 annual meeting of stockholders virtually on Jan. 30, 2026, led by President and Chief Executive Officer Gregory Gorgas. The meeting included the company's formal stockholder votes on director elections, executive compensation, and auditor ratification, followed by a question-and-answer session that ended without any submitted questions. Meeting attendance and procedures
globenewswire.com
SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, “The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers”, in Drug Discovery Today.
globenewswire.com
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo SOLANA BEACH, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo Biosciences, is presenting expanded data from Artelo's lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, ART26.12, Single Ascending Dose (SAD) Study at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit, taking place October 15–16, 2025, in Boston, Massachusetts.
See all news
